Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $137.033M Est

Benzinga Newsdesk www.benzinga.com Negative 61.0%

Neg 61% Neu 0% Pos 0%

Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $137.033 million estimate.